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Abstract
 
To investigate potential interactions between angiotensin II
(AII) and the insulin signaling system in the vasculature, in-
sulin and AII regulation of insulin receptor substrate-1
(IRS-1) phosphorylation and phosphatidylinositol (PI)
3–kinase activation were examined in rat aortic smooth
muscle cells. Pretreatment of cells with AII inhibited insu-
lin-stimulated PI 3–kinase activity associated with IRS-1 by
60%. While AII did not impair insulin-stimulated tyrosine
 
phosphorylation of the insulin receptor (IR) 
 
b
 
-subunit, it
decreased insulin-stimulated tyrosine phosphorylation of
IRS-1 by 50%. AII inhibited the insulin-stimulated associa-
tion between IRS-1 and the p85 subunit of PI 3–kinase by
30–50% in a dose-dependent manner. This inhibitory effect
of AII on IRS-1/PI 3–kinase association was blocked by the
 
AII receptor antagonist saralasin, but not by AT
 
1
 
 antagonist
losartan or AT
 
2
 
 antagonist PD123319. AII increased the
serine phosphorylation of both the IR 
 
b
 
-subunit and IRS-1.
In vitro binding experiments showed that autophosphoryla-
tion increased IR binding to IRS-1 from control cells by 2.5-
fold versus 1.2-fold for IRS-1 from AII-stimulated cells,
suggesting that AII stimulation reduces IRS-1’s ability to
associate with activated IR. In addition, AII increased p85
serine phosphorylation, inhibited the total pool of p85 asso-
ciated PI 3–kinase activity, and decreased levels of the p50/
p55 regulatory subunit of PI 3–kinase. These results suggest
that activation of the renin-angiotensin system may lead to
 
insulin resistance in the vasculature. (
 
J. Clin. Invest. 
 
1997.
 
100:2158–2169.) Key words: angiotensin II
 
 
 
• 
 
insulin receptor
substrate-1 
 
• 
 
phosphatidylinositol 3-kinase 
 
• 
 
vascular smooth
muscle cells 
 
• 
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Introduction
 
Angiotensin II (AII)
 
1
 
 is the main effector peptide of the renin–
angiotensin system (RAS) and plays an important role in the
regulation of vascular homeostasis (1, 2). Increased AII action
in the vasculature via its local induction within the vascular
wall (3–5) has been strongly implicated in the pathogenesis of
macrovascular disease by, for example, stimulating neointimal
thickening and altering vascular gene expression (6–9). Benefi-
cial effects of angiotensin converting enzyme (ACE) inhibition
on cardiovascular disease has been reported in many (for re-
view see reference 10) but not all (11) clinical trials. Recent re-
ports have also shown that inhibition of the RAS can increase
insulin sensitivity (12–14), suggesting a role for the RAS in the
regulation of insulin action. As hypertension and insulin resis-
tance often coexist and are leading risk factors for cardiovascu-
lar disease (15–18), interactions between AII and insulin sig-
naling systems may have an important role in the regulation of
vascular physiology and the development of atherosclerosis.
While several isoforms of the AII receptor have been de-
scribed, the predominant isoform expressed in macrovascular
smooth muscle cells is the AT
 
1
 
 receptor (2, 19). This receptor
is G protein–coupled to a variety of intercellular signaling path-
ways, including the phospholipase C/protein kinase C (PKC)
pathway, cytosolic calcium, and tyrosine kinases including JAK
and FAK (2, 20–22). In addition to its direct ability to regulate
growth, migration and gene expression in vascular cells (23–
25), AII may exhibit additional actions in vivo by modulating
the signaling of other hormones. Crosstalk between G pro-
tein–coupled receptors and cell surface tyrosine kinase recep-
tors (26, 27) may provide a mechanism for such indirect ac-
tions of AII on vascular cell physiology. Recently, in in vivo
studies we have shown that AII infused into the heart can both
stimulate insulin receptor substrate-1 and -2 (IRS-1, -2) ty-
rosine phosphorylation and inhibit PI 3-kinase activity associ-
ated with IRS proteins (28, 29).
The insulin receptor is a heterotetrameric tyrosine kinase
and after insulin binding undergoes a rapid tyrosine autophos-
phorylation that both activates the receptor kinase and allows
transient interaction with intracellular protein substrates in-
cluding IRS-1 and -2 via their phosphotyrosine binding do-
mains (PTB domains) (30–33). This allows tyrosine phosphor-
ylation of IRS-1 and IRS-2 on YMXM/YXXM motifs that
induces their binding to Src homology 2-domain (SH-2) con-
taining molecules, including phosphatidylinositol 3-kinase (PI
3–kinase), Grb2, SHPTP2, NCK, and Fyn (30, 32, 34, 35). The
interaction between the IRS proteins and PI 3–kinase occurs
through the p85 regulatory subunit of the enzyme resulting in
an increase in catalytic activity of the p110 subunit (34, 36, 37).
While alterations in insulin action in the vasculature, mediated
via both the insulin and IGF-1 receptors, have been proposed
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to contribute to atherosclerosis and the regulation of vascular
tone (38, 39), little is known regarding the pathways of insulin
signaling, and their regulation, in vascular cells.
In this report, we have used cultured rat aortic smooth
muscle cells (RASMC) as a model to examine the potential ef-
fects of AII on insulin signaling to IRS-1 and PI 3–kinase in
macrovascular cells. We show that AII impairs insulin stimula-
tion of IRS-1 tyrosine phosphorylation and coupling of the in-
sulin receptor pathway to PI 3–kinase. These studies suggest
that activation of the RAS may contribute to insulin resistance
in AII-responsive tissues such as the vasculature.
 
Methods
 
Cell culture.
 
RASMC were isolated from Sprague-Dawley rats as de-
scribed previously (23), cultured in Dulbecco’s minimal essential me-
dium (DMEM) containing 10% FCS, and used between passage 7
and 13. Confluent monolayers of cells were serum deprived in DMEM
containing 0.1% (wt/vol) bovine serum albumin (BSA) for 18 h be-
fore the experiment. Cells were stimulated with 100 nM AII, insulin,
or insulin-like growth factor-1 (IGF-1), 25 ng/ml platelet-derived
growth factor (PDGF), or 160 nM phorbol 12-myristate 13-acetate
(PMA) (Sigma Chemical Co., St. Louis, MO; Boehringer Mannheim
Biochemicals, Indianapolis, IN; UBI, Lake Placid, NY). AII receptor
antagonist studies were performed on cells that were pretreated for
15 min with 1 
 
m
 
M Sar
 
1
 
, Ile
 
8
 
-angiotensin (Sigma Chemical Co.), losar-
tan (provided by Dr. Ronald D. Smith, DuPont Merck Pharmaceuti-
cal Co., Wilmington, DE), or PD123319 (provided by Dr. D.G. Tay-
lor, Parke-Davis, Ann Arbor, MI) followed by stimulation with AII
and/or insulin. The effects of PI 3–kinase inhibition were examined in
cells pretreated with 50 
 
m
 
M LY294002 (BioMol) for 15 min.
 
PI 3–kinase assay.
 
Confluent 10-cm dishes of serum-deprived
RASMC were stimulated for 7 min with 100 nM AII, 5 min with 100 nM
insulin, or for 2 min with AII followed by an additional 5 min with in-
sulin. Cells were then washed twice with ice-cold PBS containing 2 mM
Na
 
2
 
VO
 
4
 
 and lysed in ice-cold freshly prepared lysis buffer containing
50 mM Hepes, pH 7.4, 137 mM NaCl, 1 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, 2 mM
Na
 
2
 
VO
 
4
 
, 10 mM sodium pyrophosphate, 100 mM sodium fluoride, 2 mM
EDTA, 2 mM phenylmethylsulfonylfluoride, 10 
 
m
 
g/ml aprotinin, 10
 
m
 
g/ml leupeptin, 10 mM benzamidine, 10% (vol/vol) glycerol, and 1%
(vol/vol) Triton X-100 for 1 h. Insoluble material was removed by
centrifugation for 15 min at 12,000 rpm at 4
 
8
 
C. 1-ml aliquots of super-
natants, normalized to protein, were incubated overnight at 4
 
8
 
C with
rabbit polyclonal antibodies against IRS-1 (29), p85 subunit of PI
3–kinase, and PDGF receptor (UBI) and the immunocomplexes
were precipitated with a 50% solution of protein A–Sepharose 6MB
(Pharmacia Biotech AB, Uppsala, Sweden). In vitro PI 3–kinase
assays were performed as described previously (34). The 
 
32
 
P-labeled
3-
 
P
 
-phosphatidylinositol was visualized using a PhosphorImager and
normalized using IMAGEQUANT software (Molecular Dynamics,
Sunnyvale, CA).
 
Immunoprecipitation and Western blotting.
 
Immunoprecipitations
of cell lysates, normalized to protein, were performed overnight at
4
 
8
 
C. Tyrosine phosphorylation of immunoprecipitated IRS-1 and IR
was detected by Western blotting using antiphosphotyrosine antibody
(4G10) followed by rabbit anti–mouse IgG (DAKO Corp., Carpente-
ria, CA) and 
 
125
 
I-protein A (Amersham Corp., Arlington Heights,
IL), as described previously (29, 34). Western blotting was performed
using antibodies against p85 (UBI) and p110
 
a
 
 or IR 
 
b
 
-subunit (Santa
Cruz Biotechnology, Santa Cruz, CA) followed by 
 
125
 
I-protein-A.
 
In vivo phosphorylation.
 
Confluent monolayers of RASMC in
15-cm plates were serum-starved for 18 h and then incubated for 4 h
in phosphate-free Eagle’s MEM (GIBCO BRL, Gaithersburg, MD)
containing 0.5 mCi/ml [
 
32
 
P]orthophosphate (DuPont-New England
Nuclear, Boston, MA). Cells were then stimulated as described
above. Labeling was terminated with liquid N
 
2
 
 and cells were thawed
 
in lysis buffer and scraped from the dish. Insoluble material was re-
moved by centrifugation for 15 min at 12,000 rpm at 4
 
8
 
C. Superna-
tants were incubated overnight at 4
 
8
 
C with antibodies directed against
IRS-1 or p85 subunit of PI 3–kinase and the immunocomplexes were
precipitated with a 50% solution of protein A–Sepharose. For in vivo
phosphorylation studies of the insulin receptor, cell lysates were cen-
trifuged at 100,000 
 
g
 
 for 30 min, the soluble fraction was applied to a
wheat germ agglutinin-Sepharose column (Sigma Chemical Co.) and
eluted with 0.3 M 
 
N
 
-acetyl-
 
D
 
-glucosamine (Sigma Chemical Co.).
The insulin receptor enriched eluates were incubated with 20 
 
m
 
g of
polyclonal anti-insulin receptor antibodies (Santa Cruz Biotechnol-
ogy) and the immunocomplexes were precipitated with a 50% solu-
tion of protein A–Sepharose 6MB. The washed immunocomplexes
were eluted with Laemmli sample buffer and separated on 6% SDS-
PAGE for the IRS-1 protein and 7.5% SDS-PAGE for the insulin re-
ceptor 
 
b
 
-subunit and p85 regulatory subunit of PI 3–kinase. Proteins
were transferred to nitrocellulose paper (0.2 
 
m
 
m pore size, Schleicher
& Schuell Inc., Keene, NH) and visualized by autoradiography. The
 
32
 
P-labeled protein bands were quantitated using IMAGEQUANT
software of the PhosphorImager.
 
Phosphoamino acid analysis.
 
The nitrocellulose containing 
 
32
 
P-
labeled IRS-1, p85 and 
 
b
 
-subunit was excised and treated with 0.5%
(wt/vol) PVP-40 (Sigma Chemical Co.) in 100 mM acetic acid for 30
min at 37
 
8
 
C. The paper was then washed five times with water and di-
gested with 10 
 
m
 
g of TPCK-trypsin (Worthington Biochemical Corp.,
Freehold, NJ) in NaHCO
 
3
 
 (pH 8.2) containing 5% acetonitrile at
37
 
8
 
C for 24 h. An additional 10 
 
m
 
g of TPCK-trypsin was added, and
the digestion was continued for 24 h. This technique consistently
eluted 90–95% of the phosphopeptides. The peptides were then evap-
orated in a Speed Vac, partially hydrolyzed in 100 
 
m
 
l of 6 N HCl at
110
 
8
 
C for 2 h, diluted in 1 ml of water and dried. Phosphoamino acid
analysis was performed by electrophoresis on cellulose thin layer
plates as described previously (40).
 
In vitro insulin receptor/IRS binding.
 
Control or AII-stimulated
(100 nM, 7 min) RASMC were harvested in ice-cold lysis buffer and
fractionated in a column using wheat germ agglutinin (WGA) Sepha-
rose. The fraction eluted with 0.3 mM 
 
N
 
-acetyl-glucosamine (NAGA)
was autophosphorylated in vitro for 30 min (40) and allowed to inter-
act with a glutathione S–transferase fusion protein containing the
PTB domain of IRS-1 (GST-IRS-1-PTB) (kindly provided by Dr. S.
Shoelson, Joslin Diabetes Center, Boston, MA). After a 2-h incuba-
tion the samples were precipitated using glutathione Sepharose 4B
(Pharmacia Biotech), separated by SDS-PAGE, and the insulin re-
ceptor associated with the GST-IRS-1-PTB was quantitated by im-
munoblotting using an antibody against the 
 
b
 
-subunit of the insulin
receptor. The flow through from the WGA column was immunopre-
cipitated with anti–IRS-1 antibody and protein A–Agarose. Immuno-
precipitates were washed three times and divided into two equal ali-
quots. WGA purified human insulin receptor (HIR) was isolated
from Chinese hamster ovary cells expressing HIR (CHO-HIRc). Equal
aliquots of HIR, autophosphorylated for 30 min at 22
 
8
 
C as described
previously (40) or used in its basal phosphorylation state, were incu-
bated with IRS-1 immunoprecipitates for 2 h at 4
 
8
 
C and washed once,
as described by Wolf et al. (41). Immunoprecipitates were separated
by SDS-PAGE and immunoblotted with antibody against the 
 
b
 
-sub-
unit of the insulin receptor followed by 
 
125
 
I-protein A.
 
Statistics.
 
Comparison of data presented as mean
 
6
 
SEM was per-
formed using the one way ANOVA or the unpaired Student’s 
 
t
 
 test as
indicated. Values of 
 
P
 
 
 
,
 
 0.05 were considered significantly different.
 
Results
 
Effects of AII, insulin, and IGF-1 on IRS-1–associated PI
3–kinase activity, insulin receptor and IRS-1 tyrosine phos-
phorylation, and IRS-1/PI 3–kinase docking.
 
The tyrosyl-phos-
phorylation of IRS-1 is necessary for its binding to SH2
domains of the p85 regulatory subunit of PI 3–kinase and its
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activation of the PI 3–kinase enzymatic activity (34, 36, 37). To
investigate the interactions between AII and insulin on the
IRS-1 signaling pathway in RASMC, cells were stimulated for
5 min with 100 nM insulin in the absence or presence of a 2
min preincubation with 100 nM AII. PI 3–kinase activity asso-
ciated with IRS-1 precipitates was measured using an in vitro
assay, and results from a typical experiment are shown in Fig. 1
 
A.
 
 A low level of IRS-1–associated PI 3–kinase activity was
present in the basal state and this was stimulated by insulin
fivefold (
 
P
 
 
 
,
 
 0.05, ANOVA). Pretreatment of cells with AII
caused a small, nonsignificant decrease in basal IRS-1 associ-
ated PI 3–kinase activity and decreased insulin stimulated IRS-1
associated PI 3–kinase activity by 60% (
 
P
 
 
 
,
 
 0.05, Fig. 1 
 
B
 
). A
time-course study of the AII effect demonstrated that simulta-
neous addition of AII and insulin, or the addition of AII 2 min
after insulin, also reduced insulin stimulation of PI 3–kinase
activity, although to a lesser extent (data not shown). A signifi-
cant IGF-1 stimulation of IRS-1 associated PI 3–kinase activity
compared with control (
 
P
 
 
 
,
 
 0.05, ANOVA) was also inhibited
by AII (Fig. 1 
 
C
 
), indicating that AII’s effect was not unique to
the insulin receptor.
To investigate the potential mechanisms responsible for
the AII-induced decrease in insulin-stimulated PI 3–kinase as-
sociated with IRS-1, effects of AII on insulin receptor and
IRS-1 tyrosine phosphorylation and IRS-1/p85 docking were
examined. RASMC were stimulated with AII and/or insulin as
described above, insulin receptor was immunoprecipitated
from WGA purified cell lysates, and tyrosine phosphorylation
of the insulin receptor 
 
b
 
-subunit was assessed by immunoblot-
ting using antiphosphotyrosine antibodies. Insulin stimulated a
fivefold increase (
 
P
 
 
 
,
 
 0.05) in tyrosine phosphorylation of the
insulin receptor in these cells (Fig. 2 
 
A
 
). Immunoprecipitation
of cell extracts with anti–IRS-1 antibodies followed by West-
ern blotting with antiphosphotyrosine antibodies revealed that
insulin also stimulated a fivefold increase in IRS-1 tyrosine
phosphorylation (Fig. 2 
 
B
 
). AII (100 nM) did not significantly
alter tyrosine phosphorylation of the insulin receptor in either
the absence or presence of insulin (Fig. 2 
 
A
 
). AII alone also
had no effect on basal IRS-1 tyrosine phosphorylation, but AII
pretreatment did inhibit insulin stimulated IRS-1 phosphoryla-
tion by 50% (Fig. 2 
 
B
 
). The AII-induced decrease in insulin-
stimulated tyrosine phosphorylation of IRS-1 was accompa-
nied by a parallel decrease in p85 binding to IRS-1 (Fig. 2 
 
C
 
).
The level of IRS-1/p85 association in the presence of AII and
insulin was significantly reduced compared with insulin stimu-
lation alone (
 
P
 
 
 
,
 
 0.05) and was not significantly different than
that in the basal state or in the presence of AII alone. The inhi-
bition of insulin-stimulated IRS-1/p85 association by AII oc-
curred in a dose-dependent manner (Fig. 3 
 
A
 
) and significant
inhibition of insulin-stimulated IRS-1/p85 docking was ob-
served in cells pretreated with 0.1 nM AII, suggesting that this
modulatory effect of AII on insulin signaling occurs at physio-
logical levels.
In order to determine if this AII effect on insulin stimu-
lated IRS-1/PI 3–kinase association was a receptor mediated
phenomenon, cells were preincubated with AII receptor
Figure 1. Effects of angiotensin II (AII), insulin, and IGF-1 on
IRS-1–associated PI 3–kinase activity in RASMC. Cells were stimu-
lated with 100 nM AII (7 min), and/or 100 nM insulin (5 min) and
IRS-1 immunoprecipitable PI 3–kinase was measured. (A) Autoradiog-
raphy of a representative experiment in triplicate. PI 3-P indicates the 
migration position of phosphatidylinositol 3-phosphate. Origin indi-
cates the migration origin of PI 3-P. (B) Bar graph shows the relative 
incorporation of 32P into PI 3-P (mean6SEM) from three separate ex-
periments. Significant differences (*P , 0.05, ANOVA) are indicated. 
(C) IRS-1–associated PI 3–kinase activity in control cells and after AII 
(7 min), IGF-1 (5 min), or AII followed by IGF-1. The bar graph shows 
the relative incorporation of 32P into PI 3-P (mean6SEM) from one 
triplicate experiment. Similar results were obtained in another tripli-
cate experiment.
Downloaded from http://www.jci.org on May 10, 2017.   https://doi.org/10.1172/JCI119752
 Regulation of Insulin Signaling in Vascular Smooth Muscle Cells
 
2161
 
antagonists Sar
 
1
 
, Ile
 
8
 
-angiotensin (saralasin), losartan, or
PD123319 followed by stimulation with the combination AII
and insulin. Saralasin, a general AII receptor antagonist, com-
pletely blocked the inhibitory effect of AII on insulin-stimu-
lated IRS-1/PI 3–kinase docking (Fig. 3 
 
B
 
). Losartan, a specific
AT
 
1
 
 receptor antagonist, and PD123319, an AT
 
2
 
 antagonist,
did not significantly alter this AII action. Similarly, saralasin
blocked AII’s inhibitory effect on IRS-1 associated PI 3–kinase
activity whereas losartan had no significant effect (Fig. 3 
 
C
 
).
These results reinforce the concept that reduction of IRS-1–asso-
ciated PI 3–kinase activity after stimulation with AII was due
to a reduction in PI 3–kinase binding to IRS-1 and was medi-
ated via a saralasin-sensitive angiotensin II receptor. Previ-
ously, we and others (23, 42) have shown that losartan inhibits
AII-stimulated PAI-1 expression and MAP kinase activation,
 
demonstrating the effectiveness of this antagonist on other AII
actions in this cell type.
 
Effects of AII and insulin on insulin receptor 
 
b
 
-subunit and
IRS-1 serine phosphorylation.
 
Increased serine phosphoryla-
tion of either the 
 
b
 
-subunit of the insulin receptor or IRS-1 is
associated with reduced insulin signaling (43–47). Since AII
has been shown to activate serine/threonine kinases, including
PKC (20), the effects of AII on the phosphorylation states of
both the insulin receptor 
 
b
 
-subunit and IRS-1 were examined.
RASMC were metabolically labeled with [
 
32
 
P]orthophosphate,
stimulated with AII and/or insulin, and either the insulin re-
ceptor or IRS-1 was immunoprecipitated. Analysis of insulin
receptor immunoprecipitates revealed that AII increased
phosphorylation of the receptor 
 
b
 
-subunit by 70% (Fig. 4 
 
A
 
).
Phosphoamino acid analysis showed that the AII-stimulated
Figure 2. Effect of AII and insulin on insulin receptor autophosphory-
lation, IRS-1 tyrosine phosphorylation, and p85 binding to IRS-1. 
RASMC were stimulated as described in Fig. 1. (A) Effect of AII on 
tyrosine phosphorylation of the insulin receptor b-subunit. Insulin re-
ceptors were immunoprecipitated from wheat germ agglutinin insulin 
receptor enriched fractions and immunoblotted with a-phosphoty-
rosine antibodies. The inset in the left upper side shows a representa-
tive Western blot of phosphotyrosyl-receptor b-subunit from control 
cells (Con) and after angiotensin II (AII), insulin (Ins) or AII followed 
by insulin. The bar graph shows the relative phosphorylation of IR
b-subunit (mean6SEM) as determined by PhosphorImager quantita-
tion of four separate experiments. Significant differences (*P , 0.05, 
ANOVA) compared with insulin treatment alone are indicated. (B) 
The inset in the left upper side shows an autoradiograph of a represen-
tative Western blot of phosphotyrosyl-IRS-1 from control cells and af-
ter AII, insulin (Ins) or AII followed by insulin. The bar graph show 
the mean of IRS-1 tyrosine phosphorylation from two separate experi-
ments performed in triplicate. (C) p85 regulatory subunit of PI
3–kinase binding to IRS-1 in control cells (con) and after AII and/or 
insulin (Ins) stimulation, as described above. P85 associated with IRS-1 
immunoprecipitate was measured as described in Methods. Inset 
shows a representative Western blot of p85 associated with IRS-1. The 
bar graph show the relative binding of p85 to IRS-1 (mean6SEM) as 
determined by PhosphorImager quantitation of three separate tripli-
cate experiments. Significant differences (*P , 0.05, ANOVA) are in-
dicated.
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increase in insulin receptor phosphorylation was due to an in-
crease in phosphoserine (Fig. 4 C). Stimulation of RASMC
with AII also increased the phosphorylation of IRS-1 by 75%
(Fig. 4 B). Again this phosphorylation was associated with an
increase in phosphoserine (Fig. 4 C). Interestingly, the magni-
tudes of AII-induced increases in total phosphorylation of
both the insulin receptor and IRS-1 were similar to that in-
duced by insulin.
The PTB domain of IRS-1 plays a key role in the docking
of IRS-1 to tyrosine 960 in the juxtamembrane region of the
insulin receptor b-subunit that allows for subsequent substrate
tyrosine phosphorylation (31, 40, 48). Thus, it can be hypothe-
sized that serine phosphorylation of the insulin receptor or
IRS-1 might influence their ability to interact with each other
for subsequent tyrosine phosphorylation events. In order to in-
vestigate this hypothesis, a glutathione S–transferase fusion
protein containing the PTB domain of IRS-1 (GST-IRS-1-
PTB) was allowed to interact in vitro with autophosphorylated
WGA purified insulin receptors from control RASMC or cells
that had been preincubated with AII for 7 min. The insulin re-
ceptor bound to GST-IRS-1-PTB was detected by Western
blotting employing anti-insulin receptor antibodies (41). Using
this assay, AII did not decrease the ability of the insulin recep-
tor to bind the PTB-domain of IRS-1 (not shown). In another
set of experiments, immunopurified IRS-1 from control
RASMC or cells treated with AII were incubated with fully
autophosphorylated WGA purified insulin receptors from
CHO cells over-expressing the HIR. In this case, AII caused a
reduction in the binding of IRS-1 to in vitro tyrosine phosphor-
ylated insulin receptors when compared to control IRS-1 (Fig.
5). This suggests that AII-induced modifications of IRS-1, pos-
sibly because of serine phosphorylation, decreases IRS-1’s
ability to associate with the tyrosine phosphorylated b-subunit
of the insulin receptor.
Since AII increased serine phosphorylation correlated with
the inhibition of insulin stimulated IRS-1/PI 3–kinase associa-
tion (Figs. 1 B and 2 C), the effect of other agents that may reg-
ulate serine phosphorylation were examined. Okadaic acid, a
serine/threonine phosphatase inhibitor has been shown to in-
duce a state of postreceptor insulin resistance by inhibiting
IRS-1 tyrosine phosphorylation and PI 3–kinase activation in
3T3-L1 adipocytes and 293 cells overexpressing IRS-1 (43, 44).
Figure 3. AII dose response and receptor antagonist effects on IRS-1/
PI 3–kinase association. (A) Dose response of AII on insulin-stimu-
lated IRS-1/p85 association. Cells were pretreated with 0.1–100 nM AII 
for 2 min followed by a 5 min stimulation with 100 nM insulin (Ins) as 
indicated. IRS-1 associated p85 was determined as described in Fig. 2 
C. Bar graph quantitation on p85 from three experiments in triplicate is 
shown. Significant differences (**P , 0.01, ANOVA) compared with 
insulin stimulation alone are indicated. (B) Effect of AII receptor an-
tagonists of IRS-1/p85 docking. Cells were pretreated for 15 min with 
AII receptor antagonist saralasin (1 mM), AT1 specific receptor antago-
nist losartan (1 mM), and AT2 antagonist PD123319 (1 mM) followed 
by the stimulation with AII and insulin as described in Fig. 2 C. IRS-1 
was immunoprecipitated and p85 was measured by immunoblotting. 
Bar graph quantitation from three experiments in triplicate is shown. 
Significant differences (*P , 0.05, ANOVA) compared with the con-
trol group (Con) are indicated. (C) Effect of AII receptor antagonists 
on IRS-1-associated PI 3–kinase activity. Cells were pretreated with sa-
ralasin and losartan and stimulated with AII and insulin as described 
above. IRS-1 associated PI 3–kinase activity was measured as described 
in Fig. 1. Bar graph quantitation of three experiments in triplicate is 
shown; significant differences (*P , 0.05, ANOVA) are indicated.
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In RASMC, okadaic acid (300 nM) inhibited insulin-stimu-
lated IRS-1 tyrosine phosphorylation and p85 binding by 30–
40%. These effects of okadaic acid are similar to those pro-
duced by AII on insulin signaling (Fig. 6 A and data not
shown). Altogether these data suggest that AII-mediated inhi-
bition of the early steps of insulin signaling could be at least
partially mediated by serine-phosphorylation, as in the case of
okadaic acid (this study and reference 43). Pretreatment of
cells with 160 nM PMA, to activate PKC also mimicked AII’s
effect, inhibiting IRS-1-associated PI 3–kinase activity by 40%.
However, PKC inhibition, by pretreatment of cells with 10 mM
bisindolylmaleimide I (GF 109203X) for 15 min, did not block
AII’s inhibitory effects on IRS-1 associated PI 3–kinase activ-
ity (not shown), suggesting that the common PKC isoforms
were not mediating this AII action.
To further investigate potential serine kinases that could be
mediating AII’s effects on IRS-1, we examined the possibility
of feedback inhibition via PI 3–kinase itself. PI 3–kinase is a
dual-specificity kinase (lipid/protein kinase) and activation of
its serine kinase has been shown to both stimulate the serine
phosphorylation of the p85 regulatory subunit and inhibit the
lipid-phosphorylating enzymatic activity of its catalytic subunit
(49, 50). Since the serine kinase activity of PI 3–kinase has
been shown to phosphorylate IRS-1 in vitro (51, 52), the effect
of PI 3–kinase inhibition on IRS-1/p85 binding was examined.
Pretreatment of RASMC with LY294002 increased p85 associ-
ation with IRS-1 induced by insulin (P , 0.05, Fig. 6 B), an ef-
fect similar to that recently reported by Rameh et al. (53).
However, PI 3–kinase inhibition did not block AII’s ability
to reduce p85 association with IRS-1, suggesting that the p85-
associated serine kinase was not responsible for AII’s effect on
p85/IRS-1 association (Fig. 6 B).
Effects of AII and PMA on p85 associated PI 3–kinase ac-
tivity and p85 phosphorylation. While the decrease in IRS-1
Figure 4. Total phosphorylation and phosphoamino acid analysis of
insulin receptor b-subunit and IRS-1 from metabolically labeled 
RASMC. Cells were labeled with [32P]orthophosphate and stimulated 
with AII and/or insulin as described in Fig. 1. (A) Immunoprecipitated 
insulin receptors were separated by SDS-PAGE, and transferred to ni-
trocellulose. A representative autoradiograph of phosphorylated
b-subunit and bar graph of quantitation (mean6SEM) from three ex-
periments are shown. (B) IRS-1 was immunoprecipitated from cells la-
beled and stimulated as described above. Autoradiograph and bar 
graph quantitation of total IRS-1 phosphorylation from two experi-
ments is shown. (C) Phosphoamino acid analysis of the insulin receptor 
and IRS-1 from control and AII-stimulated cells. Phosphoserine
(P-Ser), phosphothreonine (P-Thr), and phosphotyrosine (P-Tyr) were 
separated by thin layer electrophoresis and 32P-labeled amino acids 
were visualized by autoradiography.
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associated PI 3–kinase activity in RASMC correlates with a
decrease in IRS-1/p85 docking, in vivo studies of AII/insulin
crosstalk from cardiac tissue showed that AII could decrease
PI 3–kinase activity relative to the amount of p85 associated
with IRS-1 (29). To determine whether AII may elicit direct
effects on the p85/p110 PI 3–kinase complex, RASMC were
stimulated with 100 nM AII for 7 and 15 min or 160 nM PMA
for 15 min and p85 immunoprecipitable PI 3–kinase activity
was measured as described in the Methods. Incubation with
AII for 7 min had no effect on the p85 associated PI 3–kinase
activity, while prolonged incubation (15 min) with either AII
or PMA decreased the p85 pool of PI 3–kinase activity by 35%
(P , 0.05) and 42% (P , 0.05, ANOVA), respectively (Fig. 7
A). Immunoprecipitation of p85 from cells incubated with AII
or PMA followed by Western blotting with antibodies directed
against the p85 and the p110 catalytic subunit of PI 3–kinase
demonstrated that the amount of the two proteins was unal-
tered as compared to the basal condition. An additional pro-
tein of 50–55 kD was identified in p85 immunoblots of p85 im-
munoprecipitates with an intensity of approximately one tenth
Figure 5. In vitro binding of IRS-1 
from control or AII-stimulated 
RASMC with HIR. IRS-1 was im-
munoprecipitated from control or 
AII-stimulated cells and incubated 
with basal or in vitro autophos-
phorylated HIR. Precipitates were 
separated by SDS-PAGE and
immunoblotted with antibody 
against IR b-subunit followed by 
125I-labeled protein A. Autoradiog-
raphy and bar graph quantitation of 
b-subunit associated with IRS-1 are 
shown.
Figure 6. Effect of okadaic acid and PI 3–kinase inhibition on IRS-1 tyrosine phosphorylation and p85 association in RASMC. (A) RASMC 
were preincubated in the presence or absence of 300 nM okadaic acid for 40 min (as indicated) and then incubated with no addition (Con), insu-
lin (Ins), or AII followed by insulin as described above. IRS-1 proteins were immunoprecipitated from cleared lysates, separated by SDS-PAGE, 
transferred to nitrocellulose and revealed by monoclonal antiphosphotyrosine antibodies and 125I-protein A. A representative autoradiograph of 
tyrosine-phosphorylated IRS-1 and bar graph of quantitation (mean6SEM) from one experiment performed in triplicate are shown. Significant 
differences (*P , 0.05, ANOVA) are indicated. (B) Cells were pretreated with 50 mM LY294002 for 15 min and stimulated with insulin and AII 
as described above. IRS-1 immunoprecipitates were separated by SDS-PAGE and immunoblotted with antibody against p85 followed by 
125I-labeled protein A. An autoradiograph and bar graph quantitation of one experiment in triplicate are shown. *Significant differences 
(P , 0.05, ANOVA).
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that of p85. Interestingly, the level of this protein was reduced
by 50% (P , 0.05, ANOVA) after AII or PMA stimulation
versus the basal conditions (Fig. 7 B). This protein was recog-
nized by antibodies against the entire p85 sequence, but not by
an antibody that recognizes the SH3 domain of p85, suggesting
that these cells express one or more of the alternatively spliced
forms of the regulatory subunit of PI 3–kinase that have been
described in other cells and tissues and termed p55a and p85/
AS53 (54, 55).
Since these results suggest that AII has an effect on p85 as-
sociated PI 3–kinase above and beyond the effect of docking
to IRS-1, we examined the effect of AII on PI 3–kinase cou-
pled to tyrosine phosphorylated PDGF receptor (56). RASMC
were stimulated with AII, PDGF, or a combination of the two
hormones and PI 3–kinase activity associated with the PDGF
receptor was measured as described above. PDGF stimulated
a 30-fold increase in the PDGF receptor associated PI 3–kinase
activity. While AII alone had no significant effect on the
PDGF receptor associated PI 3–kinase activity as compared to
control, as with insulin and IGF-1, AII was able to inhibit the
PDGF stimulated PI 3–kinase activity by 30–40% (P , 0.05,
ANOVA, Fig. 7 C).
To examine the possibility that the inhibitory effects of AII
and PMA were related to changes in the phosphorylation state
of PI 3–kinase, RASMC were metabolically labeled with
[32P]orthophosphate, stimulated with AII or PMA, and the p85
subunit of PI 3–kinase was immunoprecipitated and processed
for phosphoamino acid analysis. Incubation of cells with AII
or PMA increased phosphorylation of the p85 subunit of PI
3–kinase by 50 and 150%, respectively (Fig. 8 A). Phospho-
amino acid analysis revealed that the increase in total phos-
phorylation can be accounted for by an increase in serine
phosphorylation (Fig. 8 B). A low level of phosphothreonine
labeling remained unchanged and no labeling of phosphoty-
rosine was detected in the basal state or after stimulation with
AII or PMA. Thus, AII directly alters PI 3–kinase by decreas-
ing p85 associated PI 3–kinase activity and increasing the
serine phosphorylation of p85. AII also decreases the levels of
a 50–55 kD protein which is likely an alternatively spliced form
of p85.
Figure 7. Effects of AII and PMA 
on p85-associated PI 3–kinase activ-
ity. (A) RASMC were incubated 
with no addition (Con); AII, 7 min; 
AII, 15 min; and PMA, 15 min. Cell 
lysates were immunoprecipitated 
with a-p85 antibodies and PI
3–kinase assays performed as de-
scribed in Methods. The bar graph 
shows the relative incorporation of 
32P into PI 3-P (mean6SEM) from 
four to five separate triplicate ex-
periments. Significant differences 
(*P , 0.05, ANOVA) are indicated. 
(B) p85 immunoprecipitates from 
cells treated with AII or PMA for 15 
min were separated and immuno-
blotted with antibody against p85 or 
p110. A representative autoradiograph and bar graph quantitation from three experiments in triplicate are shown. (C) PDGF receptor–associ-
ated PI 3–kinase activity in RASMC control cells and after AII (7 min), PDGF (5 min) or AII followed by PDGF. Cell lysates were immunopre-
cipitated with anti-PDGF receptor antibodies and PI 3–kinase assays were performed as described in Methods. The bar graph shows the relative 
incorporation of 32P into PI 3-P (mean6SEM) from one triplicate experiment. Similar results were obtained in another experiment performed in 
triplicate.
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Discussion
Intracellular crosstalk between different signaling systems is
one of the mechanisms by which cells can integrate multiple
hormonal signals for survival and growth. Recent studies have
demonstrated that typical G protein–coupled receptors may
activate or inhibit the signaling systems classically employed
by tyrosine kinase coupled receptors, such as mitogen acti-
vated protein kinase, PI 3–kinase, Src, FAK, and JAK2 (21, 22,
57, 58). This signal integration is particularly important to vas-
cular tissues which are in intimal contact with a variety of cir-
culating hormones. Moreover, a milieu of increased hormone
action within the vascular wall, involving the combination of
AII, insulin and PDGF, have been strongly implicated in the
neointimal formation after balloon injury and atherosclerosis
(9, 59, 60). In this report, we examined the signaling crosstalk
between these hormones in cultured aortic smooth muscle
cells.
We found that AII inhibited insulin-, IGF-1–, and PDGF-
tyrosine kinase receptor activation of the PI 3–kinase pathway.
Further analysis of AII’s effects on the insulin signaling path-
way revealed that AII inhibited insulin-stimulated tyrosine
phosphorylation of IRS-1 and its corresponding association
with the p85 subunit of PI 3–kinase. This occurred via a sarala-
sin-sensitive AII receptor–stimulated pathway that was not
blocked by the AT1 isoform antagonist losartan nor the AT2
antagonist PD123319. Previously, we and others have shown
that AII-stimulation of plasminogen activator-1 and -2 expres-
sion, and the activation of MAP kinase in these cells are AII
signaling pathways which signal via the AT1 receptor (23, 42).
A role for the AT2 receptor in AII’s inhibitory effect on insulin
signaling appears unlikely since the AT2 antagonist PD123319
had no effect on IRS-1/p85 association. Since AII’s inhibitor
effect on IRS-1/p85 docking occurs rapidly, with only a 2 min
preincubation, and at low concentrations of AII (0.1 nM), it is
unlikely that AII’s effects are mediated via biologically active
peptides (such as angiotensin III or IV) generated from the
limited proteolysis of AII. Therefore, we hypothesize that
AII’s inhibitory effects on the insulin signaling pathway in
these cells are primarily mediated via an AII receptor other
than AT1 or AT2.
Recent in vivo studies of AII/insulin crosstalk in rat heart
have shown that AII is capable of stimulating tyrosyl-phos-
phorylation of IRS-1 and IRS-2, docking with PI 3–kinase and
inhibition of its enzymatic activity, both in the basal and insu-
lin stimulated states, without affecting tyrosine phosphoryla-
tion of IRS-1 and of the insulin receptor b-subunit. These lat-
ter phenomena could be blocked by AT1 receptor antagonists
(28, 29). Thus, both in vivo and in vitro studies demonstrate
that AII inhibits insulin signaling via the PI 3–kinase pathway,
although AII exerts opposite effects on IRS-1 phosphorylation
and IRS-1/PI 3–kinase docking in heart and RASMC.
Reduced tyrosyl-phosphorylation as well as increased ser-
ine phosphorylation of the b-subunit of the insulin receptor
and IRS-1 have been proposed as mechanisms for the inhibi-
tion of insulin signaling (43–47, 61, 62). In this report, we dem-
onstrate that AII is capable of stimulating serine-phosphoryla-
tion of three crucial components of the insulin signaling
network, namely the insulin receptor itself, IRS-1 and the p85
subunit of PI 3–kinase (Fig. 9). Pretreatment of cells with AII
did not alter insulin receptor autophosphorylation, suggesting
that the decrease in IRS-1 tyrosine phosphorylation was not
due to a decrease in insulin receptor kinase activity. The ef-
fects of AII on IRS-1 in RASMC, increased IRS-1 serine
Figure 8. AII stimulates 
total phosphorylation of 
the p85 regulatory sub-
unit of PI 3–kinase. 
RASMC were in vivo
labeled with [32P]ortho-
phosphate and the immu-
noprecipitated p85 
proteins were separated 
by SDS-PAGE, trans-
ferred to nitrocellulose, 
and exposed for autoradi-
ography. The inset shows 
an autoradiograph of in 
vivo phosphorylated-p85 
regulatory subunit from 
control cells (Con) and 
after angiotensin II 
(AII), or PMA stimula-
tion. The bar graph shows 
the phosphorylation of 
p85 regulatory subunit 
(mean6SEM) as deter-
mined by PhosphorIm-
ager quantitation of two 
to three separate experi-
ments. The control and 
AII groups are signifi-
cantly different (P , 0.05, Student’s t test). (B) Phosphoamino acid analysis of p85 from control, AII (7 min) , and PMA (15 min)-stimulated 
cells was performed as described in Fig. 4 C.
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phosphorylation in association with decreased tyrosine phos-
phorylation, are reminiscent of those reported with phos-
phatase 2A inhibitor, okadaic acid (43, 44). In this study, we
also found that okadaic acid as well as phorbol ester mimicked
AII’s inhibition of PI 3–kinase associated with IRS-1 in
RASMC. Since AII increased insulin receptor and IRS-1
serine phosphorylation without impairing the insulin receptor
tyrosine kinase, we examined the possibility that AII may in-
hibit insulin-stimulated IRS-1 tyrosine phosphorylation by re-
ducing IR/IRS-1 association. Consistent with this hypothesis,
we found that IRS-1 from AII-stimulated RASMC exhibited a
decreased ability to bind autophosphorylated insulin receptor
in an in vitro assay. These results suggest that AII can reduce
insulin stimulated IRS-1 tyrosine phosphorylation by decreas-
ing the association between the receptor b-subunit and IRS-1.
Thus it is tempting to hypothesize that serine-phosphorylation
of IRS-1 impairs its docking to the autophosphorylated insulin
receptor. Alternatively, AII may decrease IRS-1/PI 3–kinase
association by rapidly inducing the tyrosine dephosphorylation
of IRS-1 via the activation or upregulation of a protein-tyro-
sine phosphatase (63).
While in RASMC the decrease in IRS-1 associated PI
3–kinase is in part due to a decrease in IRS-1/p85 docking, in
vivo studies of AII/insulin crosstalk from cardiac tissue have
shown that AII can decrease PI 3–kinase, even in the presence
of an increased amount of p85 associated with IRS-1 (29). As
these results suggested additional effects of AII on the PI
3–kinase system, the effect of AII on p85 associated PI 3–kinase
activity and p85 phosphorylation was measured. We now find
that both AII and phorbol ester significantly reduced the total
pool of PI 3–kinase activity associated with p85. The AII- or
PMA-stimulated decreases in PI 3–kinase activity could not be
explained by decreases in the total amount of immunoprecipi-
tated p85 or p110 subunits, showing that these agonists altered
the intrinsic activity rather than the amount of PI 3–kinase. In-
terestingly, IRS-1 and PI 3–kinase are also intracellular targets
for receptors other than the insulin receptor, such as growth
hormone and interferon g (64), suggesting that these inhibi-
tory effects of AII may crosstalk with other receptor pathways.
In order to determine if AII could interfere with the coupling
of PI 3–kinase to other receptor tyrosine kinase systems, we
examined the effect of AII on PDGF-receptor associated PI
3–kinase. Pretreatment of cells with AII decreased PDGF-
stimulated increases in both PI 3–kinase activity and p85 bind-
ing to the PDGF receptor. Since PI 3–kinase autophosphoryla-
tion, via a serine kinase intrinsic to the enzyme, has been
reported to act as an inhibitory feed back loop on PI 3–kinase
activity (49, 50), the effect of AII on p85 phosphorylation was
measured. These experiments demonstrated that both AII and
PMA were capable of increasing serine phosphorylation of
p85. To our knowledge this is the first evidence of a hormone-
induced serine phosphorylation and inhibition of the p85/p110
PI 3–kinase. Interestingly, both AII and PMA also decreased
the amount of a p85 isoform in these precipitates with molecu-
lar masses of z 50–55 kD. This protein(s) was recognized by a
polyclonal antibody against the entire p85 sequence but not by
a monoclonal antibody specific to the SH3 domain of p85, sug-
gesting that this protein is either the p50a or AS53 alterna-
tively spliced version of the regulatory protein of PI 3–kinase
that has been reported recently (54, 55). These results further
reinforce the finding that AII can modulate the activity of the
PI 3–kinase system.
Since the vasculature is an insulin responsive tissue, AII-
induced insulin resistance in vascular cells may play an impor-
tant role in the etiology of cardiovascular disease associated
with hypertension and noninsulin-dependent diabetes mellitus
(NIDDM). The most widely studied insulin actions in the vas-
cular cells and tissue are growth, modulation of gene expres-
sion, and the regulation of hemodynamics (38, 39, 65). Alter-
ation in these actions, mediated via both the insulin receptor
Figure 9. Diagram of AII signaling interac-
tions with the insulin receptor, IRS-1, and
PI 3–kinase in RASMC. (Arrow '1) AII in-
creases serine phosphorylation of the IR. 
(Arrow '2) AII inhibits insulin-stimulated 
tyrosine phosphorylation of IRS-1, increases 
IRS-1 serine phosphorylation, and inhibits 
insulin stimulated docking between IRS-1 
and PI 3 kinase. (Arrow '3) AII increases 
serine phosphorylation of p85 and decreases 
the intrinsic PI 3–kinase activity associated 
with the p85/p110 complex.
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and IGF-1 receptors, has been proposed to contribute to ath-
erosclerosis and abnormalities in blood flow. While the spe-
cific role of insulin-stimulated PI 3–kinase in the vasculature
has not yet been established, a recent study suggests that this
pathway is important for insulin-stimulated nitric oxide pro-
duction in endothelial cells (66). Reports from other cell types
have shown that activation of PI 3–kinase by growth factors is
a crucial step for DNA synthesis and cell division (67, 68) and,
interestingly, IRS-1 has been shown to be an important re-
quirement for cell cycle progression, cell division, and growth
(69–71). Thus, crosstalk between AII and insulin on the IRS-1/
PI 3–kinase pathway may have an important role in the regula-
tion of hemodynamics and vascular growth. The results from
this study suggest that AII, and other agents that are able to in-
duce serine phosphorylation of the IR, IRS-1, and/or PI 3–kinase,
can contribute to insulin resistance in the vasculature.
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